BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Show more
Location: Modi’in Technology Park, Hevel Modi'in, 7177871, Israel | Website: https://www.biolinerx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
17.22M
52 Wk Range
$2.30 - $26.80
Previous Close
$4.01
Open
$4.02
Volume
16,584
Day Range
$3.87 - $4.11
Enterprise Value
1.373M
Cash
28.16M
Avg Qtr Burn
-5.301M
Insider Ownership
4.08%
Institutional Own.
1.55%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist) Details Stem cell mobilization, Multiple myeloma | Approved Quarterly sales | |
Motixafortide (BL-8040) w/ cemiplimab Details Pancreatic cancer | Phase 2b Data readout | |
Motixafortide (BL-8040) w/ zimberelimab Details Pancreatic cancer, Cancer, Solid tumor/s | Phase 2b Initiation | |
Motixafortide (BL-8040) Details Sickle cell disease | Phase 1 Data readout | |
Motixafortide (BL-8040) +/- natalizumab Details Sickle cell disease | Phase 1 Data readout | |
AGI-134 Details Solid tumor/s, Cancer | Failed Discontinued | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Acute myeloid leukemia | Failed Discontinued | |
Motixafortide (BL-8040) (CXCR4 antagonist) Details Pancreatic cancer, Solid tumor/s, Cancer | Failed Discontinued |